Donald J. Hayden Jr.
Mr. Hayden has been a member of our board since December 2010. He served as non-executive chairman of the board from December 2010 to November 2018, except for the period from May 2012 to September 2012, when he acted as our Executive Chairman during a transition of senior level management. He previously served as the Executive Chairman of Transave, a biotechnology company, from 2006 until 2010, when Transave was acquired by Insmed. From 1981 to 2006, Mr. Hayden was an executive with Bristol-Myers Squibb Company, where he served in key executive roles including President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development. He previously served as chairman of the board for Vitae Therapeutics (Nasdaq: VTAE) from 2006 to 2016 until its acquisition by Allergan plc (NYSE: AGN) and on the board of directors of Amicus Therapeutics (Nasdaq: FOLD). Mr. Hayden currently serves as chairman of the board of REGENXBIO (Nasdaq: RGNX). Mr. Hayden also serves on the board of directors for the privately-held company WindMIL Therapeutics and as a director of Otsuka America Pharmaceutical, Inc., the U.S. subsidiary of Otsuka Pharmaceutical Company, Limited. Mr. Hayden holds a Bachelor of Arts degree in general studies from Harvard University and a Master of Business Administration degree from Indiana University. Mr. Hayden is a member of the Nominations and Governance Committee.